Galderma’s investigational prurigo nodularis drug hits Phase II endpoint
Prurigo nodularis is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus.
Read More
Tag: Chugai
NHS to reimburse Hemlibra
The ‘life-changing’ drug will be reimbursed for certain people with severe congenital haemophilia A.
Read More
EC extends license for Roche/Chugai’s Hemlibra
The European Commission has approved Roche and Chugai Pharma UK’s Hemlibra for the prevention of bleeding episodes in people with severe haemophilia A without factor VIII inhibitors, expanding the drug’s treatment scope.
Read More
Lilly’s snaps up Chugai’s experimental diabetes drug
Lilly has entered into an agreement to develop Chugai’s OWL833, a oral non-peptidic GLP-1 receptor agonist currently in Phase I for type II diabetes.
Read More
NICE u-turn on treatment for giant cell arteritis
Roche/Chugai’s RoActemra has now won the backing of the National Institute of Health and Care Excellence for the treatment of eligible patients with giant cell arteritis (GCA).
Read More
Roche/Chugai’s Hemlibra wins green light for bleeding disorder
The European Commission has licensed Roche/Chugai’s Hemlibra for the routine prevention of bleeding episodes in patients with haemophilia A with factor VIII inhibitors.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
